Tenet (THC) Up 14.9% Since Last Earnings Report: Can It Continue?

Tenet Healthcare (THC) reported robust second-quarter 2025 results, with adjusted EPS of $4.02, significantly surpassing estimates by 41.6% and soaring 74% year-over-year, while net operating revenues rose 3.2% to $5.3 billion. This strong performance, driven by higher facility revenues, favorable payer mix, and improved acuity, prompted the company to substantially raise its full-year 2025 guidance, with adjusted EPS now projected at $15.55-$16.21 and adjusted EBITDA between $4.4-$4.54 billion. Shares have gained 14.9% since the last earnings report, outperforming the S&P 500, reflecting positive analyst revisions and a Zacks Rank #1 (Strong Buy) outlook.

Analysis

Tenet Healthcare (THC) delivered a robust second quarter for 2025, with adjusted EPS of $4.02 soaring 74% year-over-year and surpassing consensus estimates by a significant 41.6%. This earnings power was driven by a 3.2% YoY revenue increase to $5.3 billion, operational efficiencies, and a favorable business mix. The performance was broad-based, with the Hospital Operations segment seeing a 25.1% jump in adjusted EBITDA and a 300 bps margin expansion due to higher patient acuity and a better payer mix, even as its revenue grew a modest 0.9%. Concurrently, the Ambulatory Care segment continued its expansion, posting an 11.3% revenue increase driven by facility buyouts. This strong operational execution and profitability prompted a substantial upgrade to full-year 2025 guidance, with the adjusted EPS range lifted to $15.55-$16.21, implying a 33.7% YoY increase at the midpoint. This outlook is bolstered by aggressive capital returns, including a $747 million share buyback in Q2 and a remaining authorization of $1.8 billion, supported by a 23.4% YoY growth in free cash flow. While the report highlights a minor headwind from rising supplies expense and a slight increase in long-term debt to $13.1 billion, the overwhelmingly positive results have driven shares up 14.9% and triggered a 33.86% upward revision in consensus estimates.

Key Decisions for Investors

• Given the significant earnings beat and substantial upward revision to full-year guidance, the stock's 'A' grade for value suggests fundamental strength may not be fully priced in, despite the recent 14.9% rally.
• Investors should monitor the strategic divergence between segments: the Ambulatory Care unit is the primary growth engine with guided revenue growth of 11.9%, while the larger Hospital segment's value is being driven by margin expansion and profitability improvements.
• While the aggressive $1.8 billion share buyback program is a positive signal supported by strong free cash flow, it is prudent to watch for any acceleration in operating costs and monitor the company's management of its $13.1 billion long-term debt load.